OBJECTIVE: Leptin inhibits appetite and reduces body weight. However, subcutaneous leptin administration is not very effective on weight reduction. The present studies were undertaken to test the hypotheses that nasally administered leptin effectively accesses to the brain and inhibits appetite. METHODS: Recombinant leptin (0.5 mg/rat) was administered into the bilateral nasal spaces of rats (i.n.). Changes in serum immunoreactive leptin (IRL) and cerebrospinal fluid (CSF)-IRL concentrations after i.n. leptin administration were compared after intraperitoneal (i.p.) administration. The influence of 0.1 or 0.5% lysophosphatidylcholine (LPC) as an optimizer of leptin absorption was examined. The anorexic effects of i.n. leptin were compared with i.p. leptin in ad libitum fed rats. RESULTS: The i.n. leptin increased CSF-IRL concentrations, although serum IRL concentrations of rats administered leptin i.n. were lower than those administered i.p. The addition of 0.1 and 0.5% LPC dose-dependently increased serum IRL concentrations, but did not modify CSF-IRL concentrations in i.n. leptin-treated rats. The i.n. leptin inhibited dark-time food consumption at 0-1 h and 3-6 h in ad libitum fed rats. In contrast, i.p. leptin reduced food consumption only for an hour. Phosphorylated signal transducer and activator of transcription (STAT) 3 immunoreactive cells increased in the arcuate nucleus (ARC) of the hypothalamus at 3 h only following i.n. leptin. CONCLUSION: The present study demonstrated that i.n. leptin caused longer inhibition of appetite and phosphorylation of STAT3 in ARC. It is concluded that the trans-nasal route may be useful for the selective access of leptin to the brain in obese people.
Introduction
Leptin, encoded by the ob gene, 1 inhibits appetite, and enhances sympathetic activity, resulting in a reduction of body weight gain in leptin-deficient mice. 2, 3 Genetic defects in leptin and its receptor cause severe early-onset obesity from childhood in humans. 4, 5 Obese subjects show high concentrations of circulating leptin, but do not respond to endogenously secreted leptin, indicating the existence of 'leptin resistance' in massively obese subjects. 6 The exact mechanism of the transport system for leptin into the brain has still not been clarified, but it is thought that leptin enters the brain via a saturable transport mechanism. 7 Exogenous leptin administration was expected to be useful for the treatment of massively obese patients. However, systemically administered leptin does not easily pass the blood-brain barrier (BBB) in obese people who show peripheral leptin resistance. 8 Clinical trials of leptin in obese subjects demonstrated that 20-30 times higher serum leptin concentrations than those seen physiologically might be necessary for a significant reduction of body weight. 9 The nasal route for the delivery of drugs to the brain via the olfactory region has been widely studied. 10, 11 When drugs are administered nasally, some of the drug will be absorbed into the blood stream, enter the systemic circulation, and subsequently be eliminated from the blood stream via normal clearance mechanisms. 12 The drug can only reach the brain by crossing the BBB. In addition, some drugs can be absorbed from the nose via the olfactory region into the cerebrospinal fluid (CSF), and possibly further into the brain. 10 Various studies clearly indicate that large molecules such as peptides can be transported from the olfactory region in the nasal cavity to the CSF, the olfactory bulb, and into the brain parenchyma. 10 After the nasal delivery of insulin, the brain/blood ratio was higher than for subcutaneous injection. 13 This indicates that the nasal route may be useful for the delivery of peptides to the brain. An increase of CSF leptin concentrations after continuous lumbar intrathecal leptin infusion caused a dose-dependent suppression of body weight and food consumption in rats. 14 Increased leptin in the CSF should be distributed to the target sites of leptin in the hypothalamus. From these observations, it is possible that nasal leptin administration can maintain a higher brain/blood ratio of leptin, and may be more effective in the treatment of peripheral leptin-resistant obese patients than subcutaneous leptin administration. The present studies were undertaken to examine the possibility that intranasal (i.n.) leptin administration may be more effective than peripheral leptin administration in activation of the satiety center in the hypothalamus and inhibition of appetite in rodents. In addition, we investigated the effects of an optimizer, lysophosphatidylcholine (LPC), 15, 16 on the transport of leptin to the systemic circulation and intracerebrospinal space.Materials and methods
Animals
Male Wistar rats weighing about 200 g were obtained from Clea Japan Inc. (Tokyo, Japan). The animals were individually housed in a temperature-controlled room with a 12 h illumination from 0600 to 1800, and were given food and water ad libitum, Procedures were performed with the approval of the Animal Use and Care Committee of Gunma University School of Medicine.
Leptin treatment LPC (Sigma Chem. Co., St Louis, MO, USA) was used as an optimizer of nasal leptin absorption. 15, 16 The 0.1 or 0.5% LPC was dissolved in 10% ethanol containing distilled water. Recombinant mouse leptin (0.5 mg/20 ml) (R&D Systems, Inc., Minneapolis, MN, USA) was dissolved in 10% ethanol containing distilled water with or without LPC for i.n. administration. Leptin or 10% ethanol as vehicle (10 ml in each nasal cavity) was administered i.n. through a polyethylene tube connected to a 25 ml microsyringe under intra-peritoneal (i.p.) pentobarbital anesthesia (40 mg/kg, Dainippon Pharmaceutical Co. Ltd, Osaka, Japan). Leptin was dissolved in distilled water (0.5 mg/0.1 ml) for intraperitoneal i.p. leptin administration.
Assays
For assessing changes in serum immunoreactive leptin (IRL) concentration, 200 ml of blood was collected from the jugular vein at 5, 10, 15, 30, and 60 min after the treatment. Following centrifugation at 3000 r.p.m. for 10 min, the obtained serum was immediately frozen at À201C for assay. The sum of serum IRL concentrations at every sampling time for 60 min was calculated as the area under the curve (AUC). The collection of CSF was performed by cisternal puncture with a 26-gauge needle at 60 min after treatment. 17, 18 Collection (70-80 ml per rat) was immediately terminated when blood appeared. After centrifugation, the obtained samples were frozen at À201C until assay.
Serum IRL concentrations were assayed by a commercially available radioimmunoassay (RIA) kit (Linco Research, St Charles, MO, USA). IRL concentrations in the CSF were assayed using a commercially available ELISA kit (ImmunoBiological Laboratories, Co. Ltd, Fujioka, Japan) to detect low IRL concentrations in the CSF.
Feeding test
Prior to the experiments, all animals were adapted to powdered chow for 7 days and the feeding test was conducted. The i.n. or i.p. leptin administration was performed as described above at 1800 under pentobarbital anesthesia. All animals were returned to their own cages about 30 min after awakening from the anesthesia. After returning the animals to the cages, chronological changes of dark-time food consumption were measured to the nearest 0.1 g at 1, 3, 6, and 12 h for 12 h after the treatment.
Immunohistochemistry
Phosphorylated signal transducer and activator of transcription (STAT) 3 in the arcuate nucleus (ARC) of the hypothalamus was immunostained according to the method previously described by Hosoi et al. 19 All rats were anesthetized with pentobarbital (40 mg/kg, i.p.), and slowly perfused transcardially with ice-cold 4% paraformaldehyde for 15 min. Whole brains were removed, postfixed in the same fixative for 1 h, and stored in 30% sucrose at 41C. All sections were incubated with a rabbit polyclonal antibody for phosphorylated (Tyr 705 )-STAT3 (Cell Signaling; 1:3000). Sections were then treated with biotinylated goat anti-rabbit secondary antibody (Histofine SAB-PO kit, Nichirei Co., Japan). Products of the avidin-biotin peroxidase complex were visualized with 3,3 0 -diaminobenzidine.
Western blot analysis
Following killing, rat olfactory bulbs were immediately dissected out and frozen in liquid nitrogen. The rat olfactory bulb was lysed in ice-cold Tris-buffered saline (TBS) with phenylmethylsulfonylfluoride, leupeptin, and sodium vanadate for inhibiting protease activity. 
Statistical analysis
All data represent mean7s.e.m. Differences were determined by analysis of variance (ANOVA), followed by NewmanKeuls test for the individual comparisons of the means.
Results
As shown in Figure 1a , i.p. administration of 0.5 mg leptin increased serum IRL concentrations for 60 min. In contrast, i.n. administration of 0.5 mg leptin did not show a significant increase of serum IRL concentrations in the absence of the optimizer, LPC. The addition of 0.1 and 0.5% LPC to i.n. leptin caused an increase of serum IRL concentrations in a dose-dependent manner. Changes in the AUC of serum IRL concentrations after each treatment are shown in Figure 1b . The AUC of serum IRL concentrations for 60 min was highest in the i.p. leptin-administered group. The AUC of serum IRL concentrations in the i.n. leptintreated group was significantly lower than in the i.p. leptintreated group. The addition of LPC dose-dependently increased AUC in the i.n. leptin-administered groups. The AUC of serum IRL concentrations in the i.p. leptin-treated group was about six times higher than in the i.n. leptintreated group without LPC addition. These results indicate that LPC accelerates the transport of leptin into the systemic circulation from the nasal mucosa. Changes in CSF-IRL concentrations are presented in Figure 2 . CSF-IRL concentrations in non-leptin-treated rats were about 400 pg/ml. The i.p. administration of 0.5 mg leptin increased CSF-IRL concentrations about twice as high as in non-leptin-treated rats, but the difference was not statistically significant. In contrast, i.n. administration of 0.5 mg leptin without LPC significantly (P ¼ 0.001) increased CSF-IRL concentrations to about three times higher than in non-leptin-treated rats. The effects of i.n. leptin administration with LPC were also significant compared with nonleptin treated controls (P ¼ 0.02 (0.1%), P ¼ 0.01 (0.5%)), but there were no differences in CSF-IRL concentrations among i.n. leptin treated groups by the addition of 0.1 and 0.5% LPC.
The anorexic effects of i.p. and i.n. leptin administration are presented in Figure 3a and b. Both i.p. and i.n. administration of 0.5 mg leptin significantly inhibited darktime food consumption for 1 h in ad libitum fed rats. Although the anorexic effect of i.n. leptin was not observed at 1-3 h after treatment, food consumption was significantly inhibited at 3-6 h by i.n leptin administration. No anorexic effect of leptin was found at 6-12 h after i.n. leptin treatment. Therefore, i.n. leptin administration may have a biphasic inhibitory action on feeding behavior. In contrast, i.p. leptin administration did not show any anorexic effects at 1-3, 3-6, and 6-12 h. The inhibitory effects of i.p. leptin treatment on appetite continued for only an hour after treatment.
The long form of Ob-R, Ob-Rb, is involved in the regulation of appetite through the activation of the Janus kinase (Jak)-STAT3 pathway by leptin in the feeding centers of the hypothalamus. Inhibition of appetite by nasal leptin H Shimizu et al (Figure 4b ). In contrast, phosphorylated STAT3 immunoreactivity in the ARC of the hypothalamus was not detected at 3 h after i.p. leptin administration (Figure 4a ). The results of Western blot analysis of the rat olfactory bulb are presented in Figure 5 . We confirmed that Ob-Ra (short form) is strongly expressed and Ob-Rb (long form) is weakly expressed in the olfactory bulb of the rat.
Discussion
In the present studies, we demonstrated the effectiveness of i.n. administration on the transport of leptin into the cerebroventricular space and brain of rats. I.n. administration of leptin did not increase circulating leptin concentrations significantly in the absence of an optimizer, LPC, but significantly increased CSF-IRL concentrations. An increase of CSF-IRL concentration following i.n. leptin administration caused a significant inhibition of food consumption 6 h after treatment. Therefore, it is suggested that the observed anorexic effect of leptin is not mediated by the systemic circulation. The inhibition of appetite by i.n. administered leptin may be mediated by neural transport of leptin or by an increase of CSF-IRL concentrations. In addition, the addition of the optimizer, LPC, did not affect the transport of leptin into the CSF at all, although LPC accelerates leptin absorption into the systemic circulation. This result indicates that leptin can be easily transported into the brain and CSF in the absence of any optimizers. When leptin is administered via the nasal route, no addition of optimizer may be necessary for leptin transport from the nose to the brain and intracerebroventricular space.
Two routes have been proposed for the direct passage of peptides from the nose to the brain: the intraneuronal and extraneuronal pathways. 10, 23 Intraneuronal peptide transport requires hours, but by the extraneuronal pathway, peptide rapidly passes through the intercellular clefts in the olfactory epithelium to diffuse into the subarachnoid space. The CSF-IRL concentrations were already about three times higher than in non-leptin-treated rats at 1 h after i.n. administration in the present study. Leptin may thus first reach the intracerebroventricular space through an extraneuronal pathway. It is therefore speculated that an early inhibition of appetite 1 h after treatment may be mediated by an extraneuronal pathway. In addition, a significant, delayed inhibition of feeding at 3-6 h, and phosphorylation of STAT3 in the ARC of the hypothalamus at 3 h were observed only in the i.n. leptin-treated group. We confirmed Inhibition of appetite by nasal leptin H Shimizu et al the expressions of both Ob-Ra and Ob-Rb in the rat olfactory bulb. Ob-Ra was especially strongly expressed in this region. Ob-Ra is believed to be involved in the transport of leptin in the BBB and choroid plexus. 24, 25 There may exist an additional, anorexic effect of leptin via intraneuronal pathway, perhaps mediated by Ob-Ra. Clinical studies demonstrate that continuous, subcutaneous infusions of 1.0 mg/kg/day recombinant methionyl human leptin for 1 week increased CSF leptin concentrations from 0.36 to 2.15 ng/ml, with a marked increase of serum leptin concentrations from 152.8 to 736.3 ng/ml. 26 To reduce significantly body weight in obese subjects, a marked increase of serum leptin concentrations of about 500 ng/ml should be necessary. 4 But this study did not measure CSF-IRL concentrations in patients treated with leptin. The present data indicate that i.n. leptin administration may result in CSF leptin concentrations high enough to inhibit appetite, but serum leptin concentrations remain much less than that after peripheral administration. Recently, data have accumulated that leptin has various kinds of peripheral unfavorable effects. Leptin inhibits in vitro insulin secretion and proinsulin mRNA expression in human pancreatic islets. 27 Leptin contributes to arterial thrombosis following vascular injury in vivo, perhaps through the platelet leptin receptor. 28 Leptin reduces apoptosis in endothelial cells, promoting the development of vascular proliferative disease. 29 Leptin also phosphorylates and activates tyrosine hydroxylase, and subsequently stimulates catecholamine synthesis through MAP kinase in the adrenal medulla, 30 indicating the possible involvement of peripheral leptin in the development of hypertension, in addition to the activation of sympathetic activities. Leptin stimulates in vitro lung cancer (SQ-5) cell proliferation by the activation of the MAP kinase cascade. 31 Chronic infusion of leptin into normal rats for 3 weeks fosters the development of focal glomerulosclerosis and proteinuria. 32 There is a possibility that long-term high leptin concentration in the systemic circulation during leptin treatment may, at least in part, cause unfavorable effects on obese people. It is expected that leptin administration through the trans-nasal route may reach the target sites of the hypothalamus without unnecessary increases in circulating leptin concentrations, avoiding those unfavorable peripheral effects of exogenously administered high-dose leptin in the treatment of obese people. Based on these results, it is suggested that the nasal route of leptin administration may be useful for the treatment of massively obese subjects. For clinical trials, no addition of an optimizer may be necessary for the transport of leptin into the CSF. Basic studies about i.n. drug delivery using rodents have technical limits, and a clinical study is necessary to develop the trans-nasal route of leptin administration to the brain in humans. Clinical trials of i.n. leptin administration should be performed in the near future. 
Ob-Rb (208 kDa)
Ob-Ra (116 kDa) Figure 5 Results of Western blot analysis of leptin receptor (Ob-R) expression in rat olfactory bulb. A strong expression of Ob-Ra (116 kDa) was found in rat olfactory bulb, and a weak expression of Ob-Rb (208 kDa) was also detected in this region.
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